ABT

Abbott Laboratories
D

ABT

Arincen83/100B

Abbott Laboratories EPS (earnings per share) 1985–2026

Abbott Laboratories's diluted EPS in Q3 FY2026, the three months to 30 September 2026, was 0.53 USD, down 43.6% on the same quarter a year before. Abbott Laboratories's diluted earnings per share over the last twelve months were 2.70 USD, down 66.2% on the twelve months before. In fiscal year 2025 they were 3.72 USD, down 51.3% on the year before.

Last updated 3 Nov 2026 · Next report 28 Jan 2027

EPS

Growth

Fiscal yearPeriod endingEPSGrowthEPS (basic)
TTM30 Sept 20262.70-66.16%2.70
FY202531 Dec 20253.72-51.31%3.74
FY202431 Dec 20247.64+133.64%7.67
FY202331 Dec 20233.27-16.37%3.30
FY202231 Dec 20223.91-0.76%3.94
FY202131 Dec 20213.94+57.60%3.97
FY202031 Dec 20202.50+21.36%2.52
FY201931 Dec 20192.06+53.73%2.07
FY201831 Dec 20181.34+396.30%1.35
FY201731 Dec 20170.27-71.28%0.27
FY201631 Dec 20160.94-68.03%0.95
FY201531 Dec 20152.94+96.00%3.00
FY201431 Dec 20141.50-8.54%1.51
FY201331 Dec 20131.64-56.27%1.66
FY201231 Dec 20123.75+24.58%3.78
FY201131 Dec 20113.01+1.69%3.03
FY201031 Dec 20102.96-19.78%2.98
FY200931 Dec 20093.69+21.78%3.71
FY200831 Dec 20083.03+31.17%3.06
FY200731 Dec 20072.31+106.25%2.34
FY200631 Dec 20061.12-48.15%1.12
FY200531 Dec 20052.16+4.85%2.17
FY200431 Dec 20042.06+17.71%2.07
FY200331 Dec 20031.75-1.69%1.76
FY200231 Dec 20021.78+79.80%1.79
FY200131 Dec 20010.99-44.38%1.00
FY200031 Dec 20001.78+13.38%1.80
FY199931 Dec 19991.57+5.37%1.59
FY199831 Dec 19981.49+12.03%1.52
FY199731 Dec 19971.33+11.76%1.35
FY199631 Dec 19961.19+12.26%1.21
FY199531 Dec 19951.06+13.98%1.06
FY199431 Dec 19940.93+10.71%0.93
FY199331 Dec 19930.84+13.51%0.84
FY199231 Dec 19920.74+15.63%0.74
FY199131 Dec 19910.64+14.29%0.64
FY199031 Dec 19900.56+14.29%0.56
FY198931 Dec 19890.49+16.67%0.49
FY198831 Dec 19880.42+20.00%0.42
FY198731 Dec 19870.35+20.69%0.35
FY198631 Dec 19860.29+16.00%0.29
FY198531 Dec 19850.25—0.25

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,Net income,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Abbott Laboratories's EPS

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.